SEC Form 4 · accession 0000874015-26-000212
IONIS PHARMACEUTICALS INC · IONS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brett P Monia
Officer — Chief Executive Officer · Director
Period of report
Jun 24, 2026
Accepted (ET)
Jun 26, 2026 · 7:09 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000874015
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 24, 2026 | M | 14,565 | $32.60 | A | 260,136 | D | |
| Common StockF1,F2 | Jun 24, 2026 | S | 14,565 | $78.4128 | D | 245,571 | D | |
| Common Stock | Jun 25, 2026 | M | 21,072 | $32.60 | A | 266,643 | D | |
| Common StockF1,F3 | Jun 25, 2026 | S | 21,072 | $78.49 | D | 245,571 | D | |
| Common Stock | Jun 26, 2026 | M | 50,000 | $56.78 | A | 295,571 | D | |
| Common StockF1,F4 | Jun 26, 2026 | S | 50,000 | $80.59 | D | 245,571 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy) | $32.60 | Jun 24, 2026 | M | 14,565 | D | Jan 3, 2023 | Jan 2, 2032 | Common Stock | 14,565 | 21,072 | D |
| Non-Qualified Stock Option (right to buy) | $32.60 | Jun 25, 2026 | M | 21,072 | D | Jan 3, 2023 | Jan 2, 2032 | Common Stock | 21,072 | 0 | D |
| Non-Qualified Stock Option (right to buy) | $56.78 | Jun 26, 2026 | M | 50,000 | D | Jan 4, 2022 | Jan 3, 2028 | Common Stock | 50,000 | 99,872 | D |
Explanation of responses
- F1Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.00 to $78.87 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.005 to $78.78 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80 to $81 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.